T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient recruitment, the enrollment of the first patient (First-patient-in, FPI) was accomplished in August, 2022. Meanwhile, patient recruitment is ongoing.
T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the preliminary anti-tumor activities of T-1301.
Trial information and inclusion/exclusion criteria are posted on the following website ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT05156203